Cullen Capital Management LLC Purchases 95,559 Shares of Becton, Dickinson and Company $BDX

Posted by Geri Gentry on Aug 25th, 2026

Cullen Capital Management LLC grew its holdings in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 13.1% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 824,720 shares of the medical instruments supplier’s stock after purchasing an additional 95,559 shares during the quarter. Cullen Capital Management LLC owned about 0.30% of Becton, Dickinson and Company worth $124,805,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. Auto Owners Insurance Co boosted its stake in Becton, Dickinson and Company by 22,225.2% during the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock valued at $790,079,000 after purchasing an additional 40,528,680 shares during the period. BlackRock Inc. bought a new position in Becton, Dickinson and Company in the 2nd quarter worth approximately $3,721,533,000. Wellington Management Group LLP lifted its holdings in shares of Becton, Dickinson and Company by 9,056.3% during the third quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock worth $979,290,000 after buying an additional 5,174,944 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Becton, Dickinson and Company by 13.0% in the fourth quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock valued at $7,118,282,000 after acquiring an additional 4,223,149 shares during the period. Finally, Northwestern Mutual Wealth Management Co. boosted its position in shares of Becton, Dickinson and Company by 23,219.2% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier’s stock valued at $769,397,000 after acquiring an additional 4,137,888 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at $20,380,155. This represents a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 11,704 shares of company stock worth $1,963,618 in the last 90 days. 0.40% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on BDX. Royal Bank Of Canada boosted their target price on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a research report on Thursday, August 13th. TD Cowen increased their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Piper Sandler raised their price target on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Stifel Nicolaus set a $195.00 price objective on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Finally, The Goldman Sachs Group cut their price objective on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research report on Wednesday, May 27th. Eight investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $185.67.

Check Out Our Latest Research Report on BDX

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $190.58 on Tuesday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The company has a 50-day moving average of $162.48 and a 200-day moving average of $160.73. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $193.07. The company has a market capitalization of $52.51 billion, a price-to-earnings ratio of 57.40, a PEG ratio of 13.53 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. The business had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a $1.05 dividend. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is presently 126.51%.

Becton, Dickinson and Company Profile

(Free Report)

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.